In vitro chemoresistance testing in well-differentiated carcinoid tumors

Annals of Surgical Oncology

Volumn 16, Issue 3, 2009, Pages 649-655

  Lyons, John M ^a   Abergel, Jeffrey ^b   Thomson, Jessica L ^c   Anthony, Cathy T ^a   Wang, Yi Zarn ^d   Anthony, Lowell B ^a   Boudreaux, J Philip ^d   Strauchen, James ^b   Idrees, Muhammad ^b   Warner, Richard R P ^b   Woltering, Eugene A ^a,d  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c SOUTHERN REGIONAL RESEARCH CENTER   (United States)

^d LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; PACLITAXEL; TEMOZOLOMIDE; TOPOTECAN; VINBLASTINE; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CANCER TISSUE; CARCINOID; CELL DIFFERENTIATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; TISSUE CULTURE;

ANTINEOPLASTIC AGENTS; CARCINOID TUMOR; CARCINOMA, NEUROENDOCRINE; CELL DIFFERENTIATION; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MALE; PROGNOSIS;

EID: 60449091225     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-008-0261-z     Document Type: Article

References (22)

1. Lal G, O'Dorisio T, McDougall R, et al. Cancer of the endocrine system. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG, editors. Clinical oncology. 4th ed. Philadelphia: Churchill Livingstone; 2008. p. 1290-5.
2. II Schnirer JC Yao JA Ajani 2003 Carcinoid-a comprehensive review Acta Oncol 42 672 92
3. Jensen RT, Doherty GM. Carcinoid tumors and the carcinoid syndrome. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: principles & practice of oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins, Inc.; 2005. p. 1559-74.
4. S Halford J Waxman 1998 The management of carcinoid tumours QJM 91 795 8
5. CG Moertel LK Kvols MJ O'Connell 1991 Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms Cancer 68 227 32
6. DH Kern LM Weisenthal 1990 Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures J Natl Cancer Inst 82 582 8
7. TA d'Amato RJ Landreneau RJ McKenna 2006 Prevalence of in vitro extreme chemotherapy resistance in resected nonsmall-cell lung cancer Ann Thorac Surg 81 440 6
8. CG Moertel 1983 Treatment of the carcinoid tumor and the malignant carcinoid syndrome J Clin Oncol 11 727 40
9. PF Engstrom PT Lavin CG Moertel 1984 Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor J Clin Oncol 11 1255 9
10. W Sun S Lipsitz P Catalano 2005 Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281 J Clin Oncol 23 4897 904
11. SM Ansell HC Pitot PA Burch 2001 A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors Cancer 91 1543 8
12. MH Kulke H Kim K Stuart 2004 A phase II study of docetaxel in patients with metastatic carcinoid tumors Cancer Invest 22 353 9
13. MH Kulke H Kim JW Clark 2004 A phase II trial of gemcitabine for metastatic neuroendocrine tumors Cancer 101 934 9
14. DD Von Hoff GM Clark B Stogdill 1983 Prospective clinical trial of a human tumor cloning system Cancer Res 43 1926 31
15. DD Von Hoff JF Sandbach GM Clark 1990 Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician J Natl Cancer Inst 82 110 6
16. D Schrag HS Garewal HJ Burstein 2004 American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays J Clin Oncol 22 3631 8
17. DH Kern 1997 Tumor chemosensitivity and chemoresistance assays Cancer 79 1447 50
18. V Loizzi JK Chan K Osann 2003 Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy Am J Obstet Gynecol 189 1301 7
19. RS Mehta R Bornstein IR Yu 2001 Breast cancer survival and in vitro tumor response in the extreme drug resistance assay Breast Cancer Res Treat 66 225 37
20. Kelsen DP, Cheng E, Kemeny N, et al. Streptozocin and adriamycin in the treatment of APUD tumors (Carcinoid, Islet Cell, and Medullary carcinomas of the thyroid). Proc Am Assoc Cancer Res. 1982;23:433.
21. J Frame D Kelsen N Kemeny 1988 A phase II trial of streptozotocin and adriamycin in advanced APUD tumors Am J Clin Oncol 11 490 5
22. RM Bukowski KG Johnson RF Peterson 1987 A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study Cancer 60 2891 5